BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31846507)

  • 21. Features of nonalcoholic steatohepatitis in severely obese children and adolescents undergoing sleeve gastrectomy.
    Alqahtani A; Elahmedi M; Alswat K; Arafah M; Fagih M; Lee J
    Surg Obes Relat Dis; 2017 Sep; 13(9):1599-1609. PubMed ID: 28600116
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in the United States and the Rest of the World.
    Sayiner M; Koenig A; Henry L; Younossi ZM
    Clin Liver Dis; 2016 May; 20(2):205-14. PubMed ID: 27063264
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Liver and Cardiovascular Damage in Patients With Lean Nonalcoholic Fatty Liver Disease, and Association With Visceral Obesity.
    Fracanzani AL; Petta S; Lombardi R; Pisano G; Russello M; Consonni D; Di Marco V; Cammà C; Mensi L; Dongiovanni P; Valenti L; Craxì A; Fargion S
    Clin Gastroenterol Hepatol; 2017 Oct; 15(10):1604-1611.e1. PubMed ID: 28554682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma.
    Massoud O; Charlton M
    Clin Liver Dis; 2018 Feb; 22(1):201-211. PubMed ID: 29128057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Significant burden of nonalcoholic fatty liver disease with advanced fibrosis in the US: a cross-sectional analysis of 2011-2014 National Health and Nutrition Examination Survey.
    Wong RJ; Liu B; Bhuket T
    Aliment Pharmacol Ther; 2017 Nov; 46(10):974-980. PubMed ID: 28914448
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Model for NASH and Advanced Fibrosis in Adult Patients With Diabetes and NAFLD: Guidelines for Referral in NAFLD.
    Bazick J; Donithan M; Neuschwander-Tetri BA; Kleiner D; Brunt EM; Wilson L; Doo E; Lavine J; Tonascia J; Loomba R
    Diabetes Care; 2015 Jul; 38(7):1347-55. PubMed ID: 25887357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obesity and nonalcoholic fatty liver disease: From pathophysiology to therapeutics.
    Polyzos SA; Kountouras J; Mantzoros CS
    Metabolism; 2019 Mar; 92():82-97. PubMed ID: 30502373
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modelling NAFLD disease burden in four Asian regions-2019-2030.
    Estes C; Chan HLY; Chien RN; Chuang WL; Fung J; Goh GB; Hu TH; Huang JF; Jang BK; Jun DW; Kao JH; Lee JW; Lin HC; Razavi-Shearer K; Seto WK; Wong GL; Wong VW; Razavi H
    Aliment Pharmacol Ther; 2020 Apr; 51(8):801-811. PubMed ID: 32133676
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Mechanism Analysis and Prevention of Pathogenesis of Nonalcoholic Steatohepatitis].
    Nakajima T; Naito H
    Nihon Eiseigaku Zasshi; 2015; 70(3):197-204. PubMed ID: 26411937
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can Serum Uric Acid Lowering Therapy Contribute to the Prevention or Treatment of Nonalcoholic Fatty Liver Disease?
    Paschos P; Athyros VG; Tsimperidis A; Katsoula A; Grammatikos N; Giouleme O
    Curr Vasc Pharmacol; 2018; 16(3):269-275. PubMed ID: 28676018
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Advances in diagnosis and treatment of nonalcoholic fatty liver disease].
    Zhu C; Zhou D; Fan J
    Zhonghua Gan Zang Bing Za Zhi; 2016 Feb; 24(2):81-4. PubMed ID: 26983471
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.
    Patel YA; Gifford EJ; Glass LM; McNeil R; Turner MJ; Han B; Provenzale D; Choi SS; Moylan CA; Hunt CM
    Aliment Pharmacol Ther; 2018 Jan; 47(2):268-278. PubMed ID: 29115682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Projected increase in obesity and non-alcoholic-steatohepatitis-related liver transplantation waitlist additions in the United States.
    Parikh ND; Marrero WJ; Wang J; Steuer J; Tapper EB; Konerman M; Singal AG; Hutton DW; Byon E; Lavieri MS
    Hepatology; 2019 Aug; 70(2):487-495. PubMed ID: 28833326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
    Oda K; Uto H; Mawatari S; Ido A
    Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Noninvasive evaluation of nonalcoholic fatty liver disease: Current evidence and practice.
    Zhou JH; Cai JJ; She ZG; Li HL
    World J Gastroenterol; 2019 Mar; 25(11):1307-1326. PubMed ID: 30918425
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prevalence of non alcoholic fatty liver and Non alcoholic Steatohepatitis in Peshawar Cantonment, Khyber Pakhtunkhwa, Pakistan.
    Shah AS; Khan S; Rahim H; Chishti KA; Khan AG
    Pak J Pharm Sci; 2018 Jan; 31(1):193-198. PubMed ID: 29348103
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk.
    Athyros VG; Boutari C; Stavropoulos K; Anagnostis P; Imprialos KP; Doumas M; Karagiannis A
    Curr Vasc Pharmacol; 2018; 16(3):246-253. PubMed ID: 28676019
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Impact of Nonalcoholic Fatty Liver Disease in Primary Care: A Population Health Perspective.
    Dokmak A; Lizaola-Mayo B; Trivedi HD
    Am J Med; 2021 Jan; 134(1):23-29. PubMed ID: 32931760
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.